

## References for CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Restasis® Blitz – Wave 2

1. Johnston, J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12, 2023; New Orleans, LA.
2. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
3. Effect of CEQUA in Subjects with Dry Eye Disease, ClinicalTrials.gov identifier NCT04357795. Updated February 2024. Accessed August 29, 2023. <https://www.clinicaltrials.gov/study/NCT04357795>
4. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.
5. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
6. Schechter BA, Urbieta M, Bacharach J, et al. Effect of OTX-101 on patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the phase 2b/3 clinical trial. *Clin Ophthalmol*. 2022;16:4145-4151.
7. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol*. 2018;12:1921-1929.

Current as of: August 21, 2024

© 2024 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.

PM-US-CQA-1572 08/2024